Sanara MedTech (SMTI) Cantor Global Healthcare Conference 2025 summary

Leadership and organizational development

• Newly appointed CEO brings eight years of experience, having advanced through multiple leadership roles, with official CEO duties starting September 15, 2025.

• CFO joined in January, attracted by the company's culture and growth prospects, and brings extensive finance and wound care experience.

• Leadership team has expanded from three to nearly a dozen high-talent individuals, positioning the company for future scaling.

• Focus remains on discipline, sharpening operations, and leveraging the assembled leadership team for growth.

Business evolution and growth drivers

• Transitioned from a single-product company to a diversified portfolio including soft tissue, bone fusion, and repair products.

• Achieved strong Q2 results with $25.8 million in revenue, driven by balanced growth in both soft tissue and bone repair segments.

• Notable 25% growth in bone fusion since the Scendia acquisition in 2023.

• Key growth metrics include distributor network performance, contract approvals, and surgeon engagement.

Sales strategy and distribution

• Maintains a core focus on ortho and spine, with expansion into foot, ankle, plastics, vascular, and general surgery.

• Over 400 distributor contracts in place, with significant opportunity to expand utilization within contracted facilities.

• Internal sales force size remains stable, leveraging distributor partners for broader reach.

• Currently selling into over 1,000 of 4,000 contracted facilities, indicating substantial room for growth.